1. Home
  2. DKI vs TCRT Comparison

DKI vs TCRT Comparison

Compare DKI & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DKI

DarkIris Inc. Class A Ordinary Shares

N/A

Current Price

$0.39

Market Cap

6.0M

Sector

N/A

ML Signal

N/A

Logo Alaunos Therapeutics Inc.

TCRT

Alaunos Therapeutics Inc.

HOLD

Current Price

$2.93

Market Cap

7.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DKI
TCRT
Founded
2018
1998
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0M
7.2M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
DKI
TCRT
Price
$0.39
$2.93
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
157.0K
34.5K
Earning Date
02-11-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
26.19
N/A
Revenue
$10,204,329.00
$6,000.00
Revenue This Year
N/A
$5,680,500.00
Revenue Next Year
N/A
N/A
P/E Ratio
$0.01
N/A
Revenue Growth
100.46
N/A
52 Week Low
$0.30
$1.31
52 Week High
$15.00
$6.20

Technical Indicators

Market Signals
Indicator
DKI
TCRT
Relative Strength Index (RSI) N/A 43.06
Support Level N/A $2.80
Resistance Level N/A $3.05
Average True Range (ATR) 0.00 0.27
MACD 0.00 -0.02
Stochastic Oscillator 0.00 21.53

Price Performance

Historical Comparison
DKI
TCRT

About DKI DarkIris Inc. Class A Ordinary Shares

Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.

About TCRT Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.

Share on Social Networks: